Predicting Response to Endocrine Therapy in ER-Positive Breast Cancer

D. Das

DOI: https://doi.org/10.1097/01.COT.0000754688.69484.4B

2021-06-05

Oncology Times

Abstract:A ccording to the American Cancer Society, nearly 70 percent of patients with breast cancer have hormone receptorpositive (HR+) disease—estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), or both. Hormone therapy is designed to stop the effects of estrogen on the tumor and can be very effective for ER+ breast cancer. An assortment of drugs can be prescribed as hormone therapy, and clinicians choose a treatment regimen depending on the patient and the specifics of that person’s disease. Aromatase inhibitors prevent the body from producing estrogen and are typically the first treatment of choice for hormone therapy, whereas other anti-estrogen drugs, such as fulvestrant, block the ER on cancer cells. However, there has historically been no reliable way to predict which patients will benefit, especially as the cancer advances or recurs. Furthermore, in previous research, up to 50 percent of patients with HR+ breast cancer have not responded to first-line hormone therapy, and the occurrence of non-responsiveness increased during subsequent lines of hormone therapy (Lancet 2011; doi: 10.1016/ S0140-6736(11)60993-8). New research from the Washington University School of Medicine in St. Louis has found that an imaging test measuring the function of ERs in breast cancer cells can be used to distinguish between breast cancer patients who are likely, and those who are unlikely, to benefit from hormone therapy. The findings were published in Nature Communications (2021; https://doi.org/10.1038/s41467-020-20814-9).

Medicine